Evidence map›Paper›PMID 39838657›Full record

ArticleMedicinal chemistry (Shariqah (United Arab Emirates))2025

Natural Compounds from

Aniqa Moveed, Shagufta Parveen, Nusrat Shafiq, Awais Ali, Maryam Rashid, Mohammed Bourhia, Fouad Msanda, Ahmad Mohammad Salamatullah, Simone Brogi

Abstract read
PubMed Publisher
In one paragraph

Article in Medicinal chemistry (Shariqah (United Arab Emirates)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aniqa MoveedSynthetic and Natural Product Drug Discovery Laboratory, Department of Chemistry, Government College Women University, Faisalabad, 38000, Pakistan.
Shagufta ParveenSynthetic and Natural Product Drug Discovery Laboratory, Department of Chemistry, Government College Women University, Faisalabad, 38000, Pakistan.
Nusrat ShafiqSynthetic and Natural Product Drug Discovery Laboratory, Department of Chemistry, Government College Women University, Faisalabad, 38000, Pakistan.
Awais AliDepartment of Biochemistry, Abdul wali Khan University Mardan, Pakistan.
Maryam RashidSynthetic and Natural Product Drug Discovery Laboratory, Department of Chemistry, Government College Women University, Faisalabad, 38000, Pakistan.
Mohammed BourhiaLaboratory of Biotechnology and Natural Resources Valorization, Faculty of Sciences of Agadir, Ibn Zohr University, Agadir, Morocco.
Fouad MsandaLaboratory of Biotechnology and Natural Resources Valorization, Faculty of Sciences of Agadir, Ibn Zohr University, Agadir, Morocco.
Ahmad Mohammad SalamatullahDepartment of Food Science & Nutrition, College of Food and Agricultural Sciences, King Saud University, 11 P.O. Box 2460, Riyadh, 11451, Saudi Arabia.
Simone BrogiDepartment of Pharmacy, Pisa University, Pisa, Italy.

Funding

King Saud University, Riyadh, Saudi Arabia RSP-2025R437
6 · The paper itself

Abstract

backgroundThe rise in the frequency of liver cancer all over the world makes it a prominent area of research in the discovery of new drugs or repurposing of existing drugs.

methodsThis article describes the pharmacophore-based structure-activity relationship (3DQSAR) on the secondary metabolites of

resultsOut of 59 compounds, eight ligands were found active after the 3D-QSAR study. After that, molecular docking was performed on the active compounds F72, F52, F54, F29, F37, F38, F25, and F29, which were recognized as potential targets, and the docking results showed that compound F52 (also an FDA-approved drug) was the best hit. F52 was found to be the best hit against liver cancer cell lines HCC and HepG2.

conclusionThis study would be helpful for early drug discovery optimization and lead identification.

Indexed as

Antineoplastic Agents, PhytogenicBiological ProductsCarcinoma, HepatocellularDensity Functional TheoryLiver NeoplasmsMolecular Docking SimulationMolecular Dynamics SimulationDrug Screening Assays, AntitumorHep G2 CellsHumansMolecular StructurePharmacophoreQuantitative Structure-Activity RelationshipAntineoplastic Agents, PhytogenicBiological Productscarcinomahepatoblastoma cell lineHepatocellularmalignant tumor.molecular electrostatic potentialstructure-activity relationship

Identifiers

PMID39838657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.